26 related articles for article (PubMed ID: 8088930)
1. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
[TBL] [Abstract][Full Text] [Related]
2. Duration of effect of oral diphosphonate therapy in Paget's disease of bone.
Gray RE; Yates AJ; Preston CJ; Smith R; Russell RG; Kanis JA
Q J Med; 1987 Sep; 64(245):755-67. PubMed ID: 2966965
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of Paget's disease of bone with ethane-1 hydroxy-1, 1 diphosphonate at low dosage (author's transl)].
Alexandre C; Chapuy MC; Bressot C; Vignon E; Arlot M; Mathieu L; Edouard C; Johnston CC; Meunier PJ
Nouv Presse Med; 1980 Nov; 9(45):3429-33. PubMed ID: 6777752
[TBL] [Abstract][Full Text] [Related]
4. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
5. [Short-term biological effects of synthetic salmon calcitonin in Paget's disease. Influence of posology].
Chapuy MC; Meunier P; Terrier M; David L; Vignon G
Pathol Biol (Paris); 1975 May; 23(5):349-59. PubMed ID: 172838
[TBL] [Abstract][Full Text] [Related]
6. Short courses of intravenous clodronate in the treatment of Paget's disease of bone: a long-term follow-up trial.
Broggini M; Baratelli E; Cappelli A; Marconi A; Ghiringhelli D; Salzillo A
Int J Clin Pharmacol Res; 1993; 13(6):301-4. PubMed ID: 8088930
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological therapy of Paget's and other metabolic bone diseases.
Hosking D
Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Plosker GL; Goa KL
Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
[TBL] [Abstract][Full Text] [Related]
10. [Paget's disease of the bones: diagnosis and treatment].
Jacobs JW; Huisman AM; van Paassen HC; Bijlsma JW
Ned Tijdschr Geneeskd; 1999 Apr; 143(14):719-25. PubMed ID: 10347626
[TBL] [Abstract][Full Text] [Related]
11. [Clodronate].
Franzosi MG; Devoto MA
Medicina (Firenze); 1988; 8(1):105-9. PubMed ID: 2976107
[No Abstract] [Full Text] [Related]
12. Tolerability and safety of clodronate therapy in bone diseases.
Mian M; Beghé F; Caprio A; Aloj R; Bertelli A
Int J Clin Pharmacol Res; 1991; 11(2):107-14. PubMed ID: 1831808
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]